bendamustine oral (EX-204) / Exinda Therap - LARVOL DELTA

A Triple Oral Combination of Bendamustine, Acalabrutinib, and Venetoclax Demonstrates Efficacy Against Mantle Cell Lymphoma In Vitro and In Vivo. (PubMed, Cancers (Basel)) - "Background/Objectives: Bendamustine (BEN) combined with rituximab (RTX) remains a standard first-line therapy for transplant-ineligible patients with newly diagnosed mantle cell lymphoma (MCL)... Our findings support the efficacy of oral BEN as both a monotherapy and as part of an all-oral treatment regimen for MCL. These results warrant further investigation into the clinical potential of oral BEN, particularly in combination with targeted agents."

Journal • Preclinical • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Oncology • Transplantation • ANXA5

Comparable efficacy of oral bendamustine versus intravenous administration in treating hematologic malignancies. (PubMed, Cancer Chemother Pharmacol) - "The novel oral bendamustine agent tested exhibits good oral bioavailability and systemic exposure for in-vivo antitumor efficacy comparable to IV bendamustine. An oral bendamustine formulation offers exciting clinical potential as an additional method of administration for bendamustine and warrants further evaluation in clinical studies."

Journal • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Burkitt Lymphoma • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology

Uttam Rao, MD, MBA, on Comparing Conditioning Regimens for CAR-T (CGTLive) - "Uttam Rao, MD...gave a talk on the findings from this real-world study at the 2024 Tandem Meetings |Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, held in San Antonio, Texas, February 21-24, 2024. After his presentation, CGTLive® spoke with Rao to learn more about the networks findings. Rao emphasized that the data showed that outcomes for patients receiving bendamustine and flu/cy were largely equivalent, with similar results between these patient groups for overall survival and progression-free survival at 1 year posttreatment. Furthermore, Rao noted that the severity of neutropenia was actually greater in patients receiving flu/cy, indicating that bendamustine may actually be safer in this regard. Rao concluded by discussing some of the limitations of the findings, pointing out that longer follow-up and a randomized control clinical trial could provide a greater understanding of the comparison."

Video